Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status.
<h4>Background</h4> <p>Calcium channel blockers (CCBs) may affect prostate cancer (PCa) growth by various mechanisms including those related to androgens. The fusion of the androgen-regulated gene TMPRSS2 and the oncogene ERG (TMPRSS2:ERG or T2E) is common in PCa, and prostate tum...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Wiley
2016
|
| _version_ | 1797074957741588480 |
|---|---|
| author | Geybels, MS McCloskey, KD Mills, IG Stanford, JL |
| author_facet | Geybels, MS McCloskey, KD Mills, IG Stanford, JL |
| author_sort | Geybels, MS |
| collection | OXFORD |
| description | <h4>Background</h4> <p>Calcium channel blockers (CCBs) may affect prostate cancer (PCa) growth by various mechanisms including those related to androgens. The fusion of the androgen-regulated gene TMPRSS2 and the oncogene ERG (TMPRSS2:ERG or T2E) is common in PCa, and prostate tumors that harbor the gene fusion are believed to represent a distinct disease subtype. We studied the association of CCB use with the risk of PCa, and molecular subtypes of PCa defined by T2E status.</p> <h4>Methods</h4> <p>Participants were residents of King County, Washington, recruited for population-based case–control studies (1993–1996 or 2002–2005). Tumor T2E status was determined by fluorescence in situ hybridization using tumor tissue specimens from radical prostatectomy. Detailed information on use of CCBs and other variables was obtained through inperson interviews. Binomial and polytomous logistic regression were used to generate odds ratios (ORs) and 95% confidence intervals (CIs).</p> <h4>Results</h4> <p>The study included 1,747 PCa patients and 1,635 age-matched controls. A subset of 563 patients treated with radical prostatectomy had T2E status determined, of which 295 were T2E positive (52%). Use of CCBs (ever vs. never) was not associated with overall PCa risk. However, among European-American men, users had a reduced risk of higher-grade PCa (Gleason scores ≥7: adjusted OR¼0.64; 95% CI: 0.44–0.95). Further, use of CCBs was associated with a reduced risk of T2E positive PCa (adjusted OR¼0.38; 95% CI: 0.19–0.78), but was not associated with T2E negative PCa.</p> <h4>Conclusions</h4> <p>This study found suggestive evidence that use of CCBs is associated with reduced relative risks for higher Gleason score and T2E positive PCa. Future studies of PCa etiology should consider etiologic heterogeneity as PCa subtypes may develop through different causal pathways.</p> |
| first_indexed | 2024-03-06T23:43:41Z |
| format | Journal article |
| id | oxford-uuid:702cb226-c866-496f-9ade-aa54e0c1858d |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:43:41Z |
| publishDate | 2016 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:702cb226-c866-496f-9ade-aa54e0c1858d2022-03-26T19:35:27ZCalcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:702cb226-c866-496f-9ade-aa54e0c1858dEnglishSymplectic Elements at OxfordWiley2016Geybels, MSMcCloskey, KDMills, IGStanford, JL <h4>Background</h4> <p>Calcium channel blockers (CCBs) may affect prostate cancer (PCa) growth by various mechanisms including those related to androgens. The fusion of the androgen-regulated gene TMPRSS2 and the oncogene ERG (TMPRSS2:ERG or T2E) is common in PCa, and prostate tumors that harbor the gene fusion are believed to represent a distinct disease subtype. We studied the association of CCB use with the risk of PCa, and molecular subtypes of PCa defined by T2E status.</p> <h4>Methods</h4> <p>Participants were residents of King County, Washington, recruited for population-based case–control studies (1993–1996 or 2002–2005). Tumor T2E status was determined by fluorescence in situ hybridization using tumor tissue specimens from radical prostatectomy. Detailed information on use of CCBs and other variables was obtained through inperson interviews. Binomial and polytomous logistic regression were used to generate odds ratios (ORs) and 95% confidence intervals (CIs).</p> <h4>Results</h4> <p>The study included 1,747 PCa patients and 1,635 age-matched controls. A subset of 563 patients treated with radical prostatectomy had T2E status determined, of which 295 were T2E positive (52%). Use of CCBs (ever vs. never) was not associated with overall PCa risk. However, among European-American men, users had a reduced risk of higher-grade PCa (Gleason scores ≥7: adjusted OR¼0.64; 95% CI: 0.44–0.95). Further, use of CCBs was associated with a reduced risk of T2E positive PCa (adjusted OR¼0.38; 95% CI: 0.19–0.78), but was not associated with T2E negative PCa.</p> <h4>Conclusions</h4> <p>This study found suggestive evidence that use of CCBs is associated with reduced relative risks for higher Gleason score and T2E positive PCa. Future studies of PCa etiology should consider etiologic heterogeneity as PCa subtypes may develop through different causal pathways.</p> |
| spellingShingle | Geybels, MS McCloskey, KD Mills, IG Stanford, JL Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status. |
| title | Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status. |
| title_full | Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status. |
| title_fullStr | Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status. |
| title_full_unstemmed | Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status. |
| title_short | Calcium channel blocker use and risk of prostate cancer by TMPRSS2:ERG gene fusion status. |
| title_sort | calcium channel blocker use and risk of prostate cancer by tmprss2 erg gene fusion status |
| work_keys_str_mv | AT geybelsms calciumchannelblockeruseandriskofprostatecancerbytmprss2erggenefusionstatus AT mccloskeykd calciumchannelblockeruseandriskofprostatecancerbytmprss2erggenefusionstatus AT millsig calciumchannelblockeruseandriskofprostatecancerbytmprss2erggenefusionstatus AT stanfordjl calciumchannelblockeruseandriskofprostatecancerbytmprss2erggenefusionstatus |